Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas

R. I. Jakacki, C. Jamison, Vincent Mathews, D. K. Hellman, Edward Dropcho, Kenneth Cornetta, D. R. Macdonald, D. A. Williams

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. The regimen of procarbazine, CCNU, and vincristine is active against gliomas. Previous attempts at dose-intensification have been unsuccesful because of delayed and cumulative myelosuppression. We sought to determine whether peripheral blood stem cell (PBSC) infusions would allow dose-escalation and time compression. Procedure. Eleven patients, age 2.8- 35.9 years, with newly diagnosed (n = 10) or recurrent (n = 1) gliomas underwent PBSC harvesting after mobilization with G-CSF. Chemotherapy consisted of CCNU 130 mg/m2 on day 0, vincristine 1.5 mg/m2 on days 0 and 7, and procarbazine 150 mg/m2 on days 1-7. PBSCs were reinfused on day 9 of each course. Four courses of chemotherapy were administered 28 days apart or when counts recovered. Involved field radiation was administered to newly diagnosed high-grade glioma patients following recovery from chemotherapy. Results. Compared to the standard PCV regimen given every 6 weeks, dose intensity received was 1.7- and 1.8-fold greater for CCNU and procarbazine. Chemotherapy was delivered on time in 33/41 (80.5%) courses. Four courses (9.8%) were complicated by absolute neutrophil counts <200/μL; platelet nadirs < 50,000/μL occurred in two courses (4.9%). Fever with neutropenia complicated three courses. Eight of 9 patients with measurable disease had an objective decrease in tumor size and/or decreased enhancement. Median survival for patients with high-grade gliomas (n = 6) was 13 months. Conclusions. Dose-intensification of PCV is possible using PBSCs.

Original languageEnglish
Pages (from-to)483-490
Number of pages8
JournalMedical and Pediatric Oncology
Volume31
Issue number6
DOIs
StatePublished - 1998

Fingerprint

Lomustine
Procarbazine
Vincristine
Glioma
Drug Therapy
Granulocyte Colony-Stimulating Factor
Neutropenia
Neutrophils
Fever
Blood Platelets
Radiation
Survival
Peripheral Blood Stem Cells
Neoplasms

Keywords

  • CCNU
  • Dose-intensity
  • Gliomas
  • Peripheral blood stem cell
  • Procarbazine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. / Jakacki, R. I.; Jamison, C.; Mathews, Vincent; Hellman, D. K.; Dropcho, Edward; Cornetta, Kenneth; Macdonald, D. R.; Williams, D. A.

In: Medical and Pediatric Oncology, Vol. 31, No. 6, 1998, p. 483-490.

Research output: Contribution to journalArticle

@article{628cebdfa22d4fa0a16b117a6d52a7d0,
title = "Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas",
abstract = "Background. The regimen of procarbazine, CCNU, and vincristine is active against gliomas. Previous attempts at dose-intensification have been unsuccesful because of delayed and cumulative myelosuppression. We sought to determine whether peripheral blood stem cell (PBSC) infusions would allow dose-escalation and time compression. Procedure. Eleven patients, age 2.8- 35.9 years, with newly diagnosed (n = 10) or recurrent (n = 1) gliomas underwent PBSC harvesting after mobilization with G-CSF. Chemotherapy consisted of CCNU 130 mg/m2 on day 0, vincristine 1.5 mg/m2 on days 0 and 7, and procarbazine 150 mg/m2 on days 1-7. PBSCs were reinfused on day 9 of each course. Four courses of chemotherapy were administered 28 days apart or when counts recovered. Involved field radiation was administered to newly diagnosed high-grade glioma patients following recovery from chemotherapy. Results. Compared to the standard PCV regimen given every 6 weeks, dose intensity received was 1.7- and 1.8-fold greater for CCNU and procarbazine. Chemotherapy was delivered on time in 33/41 (80.5{\%}) courses. Four courses (9.8{\%}) were complicated by absolute neutrophil counts <200/μL; platelet nadirs < 50,000/μL occurred in two courses (4.9{\%}). Fever with neutropenia complicated three courses. Eight of 9 patients with measurable disease had an objective decrease in tumor size and/or decreased enhancement. Median survival for patients with high-grade gliomas (n = 6) was 13 months. Conclusions. Dose-intensification of PCV is possible using PBSCs.",
keywords = "CCNU, Dose-intensity, Gliomas, Peripheral blood stem cell, Procarbazine",
author = "Jakacki, {R. I.} and C. Jamison and Vincent Mathews and Hellman, {D. K.} and Edward Dropcho and Kenneth Cornetta and Macdonald, {D. R.} and Williams, {D. A.}",
year = "1998",
doi = "10.1002/(SICI)1096-911X(199812)31:6<483::AID-MPO4>3.0.CO;2-9",
language = "English",
volume = "31",
pages = "483--490",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas

AU - Jakacki, R. I.

AU - Jamison, C.

AU - Mathews, Vincent

AU - Hellman, D. K.

AU - Dropcho, Edward

AU - Cornetta, Kenneth

AU - Macdonald, D. R.

AU - Williams, D. A.

PY - 1998

Y1 - 1998

N2 - Background. The regimen of procarbazine, CCNU, and vincristine is active against gliomas. Previous attempts at dose-intensification have been unsuccesful because of delayed and cumulative myelosuppression. We sought to determine whether peripheral blood stem cell (PBSC) infusions would allow dose-escalation and time compression. Procedure. Eleven patients, age 2.8- 35.9 years, with newly diagnosed (n = 10) or recurrent (n = 1) gliomas underwent PBSC harvesting after mobilization with G-CSF. Chemotherapy consisted of CCNU 130 mg/m2 on day 0, vincristine 1.5 mg/m2 on days 0 and 7, and procarbazine 150 mg/m2 on days 1-7. PBSCs were reinfused on day 9 of each course. Four courses of chemotherapy were administered 28 days apart or when counts recovered. Involved field radiation was administered to newly diagnosed high-grade glioma patients following recovery from chemotherapy. Results. Compared to the standard PCV regimen given every 6 weeks, dose intensity received was 1.7- and 1.8-fold greater for CCNU and procarbazine. Chemotherapy was delivered on time in 33/41 (80.5%) courses. Four courses (9.8%) were complicated by absolute neutrophil counts <200/μL; platelet nadirs < 50,000/μL occurred in two courses (4.9%). Fever with neutropenia complicated three courses. Eight of 9 patients with measurable disease had an objective decrease in tumor size and/or decreased enhancement. Median survival for patients with high-grade gliomas (n = 6) was 13 months. Conclusions. Dose-intensification of PCV is possible using PBSCs.

AB - Background. The regimen of procarbazine, CCNU, and vincristine is active against gliomas. Previous attempts at dose-intensification have been unsuccesful because of delayed and cumulative myelosuppression. We sought to determine whether peripheral blood stem cell (PBSC) infusions would allow dose-escalation and time compression. Procedure. Eleven patients, age 2.8- 35.9 years, with newly diagnosed (n = 10) or recurrent (n = 1) gliomas underwent PBSC harvesting after mobilization with G-CSF. Chemotherapy consisted of CCNU 130 mg/m2 on day 0, vincristine 1.5 mg/m2 on days 0 and 7, and procarbazine 150 mg/m2 on days 1-7. PBSCs were reinfused on day 9 of each course. Four courses of chemotherapy were administered 28 days apart or when counts recovered. Involved field radiation was administered to newly diagnosed high-grade glioma patients following recovery from chemotherapy. Results. Compared to the standard PCV regimen given every 6 weeks, dose intensity received was 1.7- and 1.8-fold greater for CCNU and procarbazine. Chemotherapy was delivered on time in 33/41 (80.5%) courses. Four courses (9.8%) were complicated by absolute neutrophil counts <200/μL; platelet nadirs < 50,000/μL occurred in two courses (4.9%). Fever with neutropenia complicated three courses. Eight of 9 patients with measurable disease had an objective decrease in tumor size and/or decreased enhancement. Median survival for patients with high-grade gliomas (n = 6) was 13 months. Conclusions. Dose-intensification of PCV is possible using PBSCs.

KW - CCNU

KW - Dose-intensity

KW - Gliomas

KW - Peripheral blood stem cell

KW - Procarbazine

UR - http://www.scopus.com/inward/record.url?scp=0031785402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031785402&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199812)31:6<483::AID-MPO4>3.0.CO;2-9

DO - 10.1002/(SICI)1096-911X(199812)31:6<483::AID-MPO4>3.0.CO;2-9

M3 - Article

VL - 31

SP - 483

EP - 490

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -